Literature DB >> 1819745

Stereospecific synthesis of antitumor active thioether PAF analogs.

S K Bhatia1, J Hajdu.   

Abstract

A novel stereospecific synthesis of antitumor active thioether analogs of platelet-activating factor (PAF) is reported. The synthesis is based upon: i) the use of D-serine to provide the chiral center for the construction of the optically active phospholipid molecule; ii) development of the sn-1-thioalkyl function via thioacetate displacement of methanesulfonate-activated primary hydroxyl group followed by alkylation of the sn-1-thiolate function; and iii) introduction of the phosphocholine moiety through the 2-chloro-2-oxo-1,3,2-dioxaphospholane/trimethylamine sequence. The entire scheme relies on the use of a single protecting group. The synthetic thioether phospholipid 1-S-hexadecyl-2-N-acetamidodeoxy-sn-glycero-3-phosphocholine has been shown to be a potent antitumor active phospholipid, exhibiting tumor cytotoxicity against a lymphoblastoid lymphoma (Li-A) cell line and a malignant histiocytic (DHL-4) cell line of human origin at the same level of potency as ET-18-OMe and 1-O-octadecyl-2-N-acetamidodeoxy-sn-glycero-3-phosphocholine. The synthetic method described has a great deal of flexibility, providing a convenient general route to a wide range of thioether PAF analogs.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1819745     DOI: 10.1007/BF02536580

Source DB:  PubMed          Journal:  Lipids        ISSN: 0024-4201            Impact factor:   1.880


  11 in total

1.  A SIMPLE, SPECIFIC SPRAY FOR THE DETECTION OF PHOSPHOLIPIDS ON THIN-LAYER CHROMATOGRAMS.

Authors:  J C DITTMER; R L LESTER
Journal:  J Lipid Res       Date:  1964-01       Impact factor: 5.922

2.  Tissue sulfhydryl groups.

Authors:  G L ELLMAN
Journal:  Arch Biochem Biophys       Date:  1959-05       Impact factor: 4.013

3.  Concluding remarks.

Authors:  O Westphal
Journal:  Lipids       Date:  1987-11       Impact factor: 1.880

Review 4.  Ether lipids and analogs in experimental cancer therapy. A brief review of the Munich experience.

Authors:  W E Berdel
Journal:  Lipids       Date:  1987-11       Impact factor: 1.880

5.  Phase I trial of the thioether phospholipid analogue BM 41.440 in cancer patients.

Authors:  D B Herrmann; H A Neumann; W E Berdel; M E Heim; M Fromm; D Boerner; U Bicker
Journal:  Lipids       Date:  1987-11       Impact factor: 1.880

6.  Synthesis of sulfur analogues of alkyl lysophospholipid and neoplastic cell growth inhibitory properties.

Authors:  S Morris-Natschke; J R Surles; L W Daniel; M E Berens; E J Modest; C Piantadosi
Journal:  J Med Chem       Date:  1986-10       Impact factor: 7.446

7.  Cytotoxicity of thioether-lysophospholipids in leukemias and tumors of human origin.

Authors:  W E Berdel; M Fromm; U Fink; W Pahlke; U Bicker; A Reichert; J Rastetter
Journal:  Cancer Res       Date:  1983-11       Impact factor: 12.701

8.  Cytotoxicity of platelet activating factor and related alkyl-phospholipid analogs in human leukemia cells, polymorphonuclear neutrophils, and skin fibroblasts.

Authors:  D R Hoffman; J Hajdu; F Snyder
Journal:  Blood       Date:  1984-03       Impact factor: 22.113

9.  Effect of alkyl-lysophospholipids on phosphatidylcholine biosynthesis in leukemic cell lines.

Authors:  W R Vogler; E Whigham; W D Bennett; A C Olson
Journal:  Exp Hematol       Date:  1985-08       Impact factor: 3.084

10.  Antileukemic agent alkyllysophospholipid regulates phosphorylation of distinct proteins in HL60 and K562 cells and differentiation of HL60 cells promoted by phorbol ester.

Authors:  Z Kiss; E Deli; W R Vogler; J F Kuo
Journal:  Biochem Biophys Res Commun       Date:  1987-02-13       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.